Dublin 8

• Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Ga … Ended
  2023-504834-23-00 11 2021-02-24 Advanced/Metastatic Gastroesophageal Adenocarcinoma
• Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants wit … Ended
  2023-508443-40-00 5 2020-12-18 Lung Cancer, Non-Small Cell
• A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (AcceleRET-Lung) Ended
  2023-505035-12-00 5 2020-06-12 RET fusion−positive, metastatic Non-Small Cell Lung Cancer
• A study of nivolumab and ipilimumab in untreated patients with stage 3 NSCLC that is unable or not planned to be removed by surgery Ended
  2022-502886-71-00 5 2019-11-20 Previously Untreated Locally Advanced Non-small Cell Lung Cancer (LA N
• Phase 3 study of pembrolizumab plus lenvatinib in endometrial carcinoma Ended
  2023-505614-17-00 5 2019-09-20 Participants with advanced or recurrent endometrial carcinoma
• A study comparing current standard therapies with fedratinib for the treatment of myelofibrosis (either diagnosed alone or after polycythemi … Ended
  2024-511972-33-00 5 2019-08-05 Primary myelofibrosis, post-polycythemia vera myelofibrosis , or post-
• Pembrolizumab as adjuvant therapy for resectable high-risk LA cSCC Ended
  2022-500395-57-00 5 2019-03-04 Resectable high-risk Locally Advanced Cutaneous Squamous Cell Carcinom
• Evaluation of Upadacitinib in Adolescent and Adult Patients with Moderate to Severe Atopic Dermatitis (Eczema) – Measure Up 2 Ended
  2022-502936-38-00 5 2019-01-09 Moderate and Severe Atopic Dermatitis
• Pembrolizumab/placebo plus chemotherapy as first-line therapy in participants with HER2 negative advanced gastric or GEJ adenocarcinoma Ended
  2023-508890-10-00 5 2018-12-05 Gastric and gastric esophageal junction (GEJ) adenocarcinoma
• A phase III trial investigating a gene therapy (AAV-hFIXco-Padua, AMT061), in adult patients with severe or moderately severe haemophilia B, … Ended
  2024-510738-42-00 5 2018-12-03 Haemophilia B
• Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in HER2 Positive Advanced Gastric or GEJ Adenocarcinoma Ended
  2023-508253-98-00 5 2018-10-05 Gastric or gastroesophageal junction (GEJ) adenocarcinoma
• A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC af … Ended
  2023-509137-39-00 5 2015-11-06 Stage IB (T ≥ 4 cm), II and IIIA NSCLC
• A Phase 3 Study to Evaluate the Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants with Relapsed or Ref … Ended
  2023-509472-42-00 5 Relapsed and/or Refractory Multiple Myeloma
• A Clinical Study of Mitapivat in Patients with Sickle Cell Disease and Kidney Disease Ended
  2023-510289-28-00 4 Sickle Cell Disease (SCD) and Nephropathy
• A study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fall … Ended
  2024-512477-27-00 4 Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primar
• Study on Pharmacokinetics of newly developed ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) Ended
  2024-515487-31-00 6 HIV-infected

Showing 145–160 of 160 trials